ACTR-06. CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: HALF-WAY REPORT

Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated methylguanine DNA-methyltransferase (MGMT gene, which confers a limited response to standard of care treatment with temozolomide (TMZ) resulting in a lower survival. VAL-083 is a novel bi-functional DNA targeting age...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Chen, Zhong-ping, Guo, Chengcheng, Yang, Qun-ying, Li, Jia-wei, Wu, Shao-xiong, Bacha, Jeffrey, Johnson, Gregory, Langlands, John, Kwan, Claire, Kanekal, Sarath, Schwartz, Richard, Lopez, Lorena, Brown, Dennis
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Adult Clinical Trials - Non-Immunologic
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847153/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.050
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares